文献速递妇科

年轻与老年女性高级别浆液性卵巢癌的分子特征对比

Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
PubMed 文献 · Gynecol Oncol · 2021-03-03

本研究比较年轻与老年高级别浆液性卵巢癌(HGSOC)患者的突变图谱和同源重组DNA修复缺陷(HRD)基因组特征。对15例年轻和15例老年患者进行全外显子测序,并用TCGA数据(38例年轻、30例老年)验证。结果显示老年患者致病性胚系BRCA1突变和HRD基因组特征较少,CCNE1扩增较多,提示老年患者PARP抑制剂个体化治疗可能需要考虑。

要点

  • 老年HGSOC患者致病性胚系BRCA1突变频率低于年轻患者。
  • 年轻HGSOC患者更常见HRD基因组特征和HRD基因签名富集。
  • 老年HGSOC患者更常见CCNE1扩增和增殖型CLOVAR亚型。

核心结论

  • 老年HGSOC患者较年轻患者较少携带致病性胚系BRCA1突变和HRD基因组特征。
  • 老年女性可能需要个体化治疗选择,尤其涉及PARP抑制剂的使用。

研究设计与样本

  • 机构队列:15例年轻(中位49岁,范围35-53)和15例老年(中位72岁,范围70-87)HGSOC患者接受全外显子测序(WES)。
  • 验证队列:TCGA数据包括38例年轻(中位45岁,范围34-50)和30例老年(中位74岁,范围68-84)HGSOC患者的WES数据。
  • 评估突变谱、BRCA1/2状态、基因组HRD特征,TCGA病例还评估基于RNA测序的HRD转录组签名。

主要发现

  • 机构队列中,年轻患者致病性胚系BRCA1/2突变频率为5/15,老年患者为0/15(p = 0.042)。
  • TCGA队列中,年轻患者致病性胚系BRCA1突变频率为8/38,老年患者为0/30(p = 0.007);BRCA2突变频率年轻3/38,老年4/30(p = 0.691)。
  • 两个队列均未发现体细胞BRCA1/2突变。
  • 老年患者HGSOC更常见衰老相关突变签名,机构队列中CCNE1扩增为3/15(20%)。
  • TCGA队列中,年轻患者HGSOC更常见HRD基因组特征(所有p < 0.05)和显著HRD基因签名富集,CCNE1扩增较少(p = 0.05)。

关键数值与推荐

  • 年轻和老年定义分别为年龄最低和最高四分位数。
  • 机构队列年轻患者中位年龄49岁(范围35-53),老年患者中位年龄72岁(范围70-87)。
  • TCGA队列年轻患者中位年龄45岁(范围34-50),老年患者中位年龄74岁(范围68-84)。

临床怎么用

  • 对老年HGSOC患者,应关注其较低概率携带胚系BRCA1突变和HRD特征,PARP抑制剂使用需个体化评估。
  • 年轻HGSOC患者更可能从HRD相关治疗中获益,但需结合基因检测结果。

局限性

  • 机构队列样本量较小(各15例)。
  • TCGA验证队列为回顾性数据,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine if the mutational landscapes and genomic features of homologous recombination DNA repair defects (HRD) vary between younger and older patients with high-grade serous ovarian cancer (HGSOC). METHODS: Younger and older women were defined as bottom and top age quartiles, respectively. HGSOCs from 15 younger (median 49 years, range 35-53) and 15 older women (median 72 years, range 70-87) were subjected to whole-exome sequencing (WES). For validation, HGSOC WES data were obtained from The Cancer Genome Atlas (TCGA), including 38 younger (median 45 years, range 34-50) and 30 older women (median 74 years, range 68-84). Mutational profiles, BRCA1/2 status, genomic HRD features, and for TCGA cases RNA-sequencing-based HRD transcriptomic signatures were assessed. RESULTS: In the institutional cohort, pathogenic germline BRCA1/2 mutations were more frequent in younger (5/15) than older women (0/15, p = 0.042). No somatic BRCA1/2 mutations were identified. HGSOCs from older patients preferentially displayed aging-related mutational signatures and, in contrast to younger patients, harbored CCNE1 amplifications (3/15, 20%). In the TCGA cohort, pathogenic germline BRCA1 (younger 8/38, older 0/30, p = 0.007) but not BRCA2 mutations (young 3/38, older 4/30, p = 0.691) were more frequent in younger patients. Again, no somatic BRCA1/2 mutations were identified. HGSOCs from younger women more frequently displayed genomic features of HRD (all, p < 0.05), a significant HRD gene-signature enrichment, but less frequently CCNE1 amplification (p = 0.05). Immunoreactive CLOVAR subtypes were more common in HGSOCs from younger women, and proliferative subtypes in HGSOCs from older women (p = 0.041). CONCLUSIONS: HGSOC patients diagnosed at an older age less frequently harbor pathogenic BRCA1 germline mutations and genomic features of HRD than younger women. Individualized treatment options, particularly pertaining to use of PARP inhibitors, in older women may be warranted.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Filippova OT, Selenica P, Pareja F, et al. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women. Gynecol Oncol. 2021. PMID: 33674143. doi:10.1016/j.ygyno.2021.02.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。